Company news

Alkermes plc news in 2024

Alkermes plc's news releases, calls and decks from 2024, newest first.

View company

Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences

November 6, 2024

Alkermes plc Reports Third Quarter 2024 Financial Results

October 23, 2024

Alkermes to Report Third Quarter Financial Results on October 24, 2024

October 16, 2024

Alkermes to Host Investor Event to Review Orexin Portfolio Strategy

September 24, 2024

Alkermes to Present Positive Clinical Data From Phase 1b Study of ALKS 2680 in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia at Sleep Europe 2024

September 22, 2024

Alkermes to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference

September 18, 2024

Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program

September 12, 2024

Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

August 27, 2024

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

August 21, 2024

Alkermes plc Reports Second Quarter 2024 Financial Results

July 23, 2024

Alkermes to Report Second Quarter Financial Results on July 24, 2024

July 16, 2024

Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024

June 2, 2024

Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

May 27, 2024

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

May 13, 2024

Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk

May 1, 2024

Alkermes plc Reports First Quarter 2024 Financial Results

April 30, 2024

Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

April 23, 2024

Alkermes to Report First Quarter Financial Results on May 1, 2024

April 16, 2024

Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia

April 8, 2024

Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

April 7, 2024

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

March 6, 2024

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024

February 14, 2024

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024

February 7, 2024

Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)

January 2, 2024

Calls in 2024

Decks in 2024